Susan Talamini, MD
Urology · San Antonio, TXNPI 1023470796
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Intuitive Surgical at 53.5% of the total. Reporting peaked in 2024 at $1,470 and has fallen 88.0% since, to $177 in 2025. That places this record below the midpoint for urology clinicians in TX, where the typical reported total is $3,394.
Across 41 payments — averaging $55.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Boston Scientific$246
- Calyxo, Inc.$142
- Myriad Genetic Laboratories, Inc.$76
- Sumitomo Pharma America, Inc.$69
- Coloplast$60
- plus $461 from 13 others
What the payments were for
- Speaking & faculty fees$151%
- Travel & lodging$1,04046%
- Food & beverage$1,20553%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $1,212 |
| Boston Scientific | 5 | $246 |
| Calyxo, Inc. | 1 | $142 |
| Myriad Genetic Laboratories, Inc. | 2 | $76 |
| Sumitomo Pharma America, Inc. | 3 | $69 |
| Coloplast | 1 | $60 |
| AstraZeneca | 2 | $59 |
| Olympus America Inc. | 2 | $57 |
| Astellas Pharma US Inc | 2 | $50 |
| Blue Earth Diagnostics | 2 | $50 |
| Procept Biorobotics Corporation | 1 | $49 |
| Johnson & Johnson | 2 | $49 |
| Bayer | 2 | $41 |
| Merck | 1 | $27 |
| Novartis | 1 | $21 |
| AbbVie | 1 | $21 |
| Pfizer | 1 | $16 |
| BD | 1 | $15 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,266 in reported general payments places this provider in the 35th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 33 | $23,713 |
| Estradiol | 38 | $2,595 |
| Trospium Chloride ErTrospium Chloride | 11 | $1,996 |
| Tamsulosin Hcl | 146 | $1,680 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 33 | $1,528 |
| Oxybutynin Chloride ErOxybutynin Chloride | 103 | $1,118 |
| Finasteride | 95 | $962 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 17 | $474 |
| Cefdinir | 31 | $341 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 30 | $306 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 27 | $135 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $76 |
| Levofloxacin | 20 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $50 | $23,71333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 878 urology providers in Texas.
Other urology in San Antonio
- Daniel SaltzsteinSan Antonio$547K
- Leroy JonesSan Antonio$506K
- Jose de la CerdaSan Antonio$278K
- Naveen KellaSan Antonio$84K
- Christopher CantrillSan Antonio$73K
- Robert SvatekSan Antonio$51K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
- Allen MoreyDallas$914K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.